JP2007508242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508242A5 JP2007508242A5 JP2006522433A JP2006522433A JP2007508242A5 JP 2007508242 A5 JP2007508242 A5 JP 2007508242A5 JP 2006522433 A JP2006522433 A JP 2006522433A JP 2006522433 A JP2006522433 A JP 2006522433A JP 2007508242 A5 JP2007508242 A5 JP 2007508242A5
- Authority
- JP
- Japan
- Prior art keywords
- thromboxane
- receptor antagonist
- cox
- inhibitor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims description 45
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims description 44
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 229960003422 indobufen Drugs 0.000 claims description 20
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 claims description 20
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 20
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 20
- 150000003180 prostaglandins Chemical class 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims description 17
- 229950004274 ifetroban Drugs 0.000 claims description 17
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000008331 benzenesulfonamides Chemical class 0.000 claims description 9
- 230000002195 synergetic effect Effects 0.000 claims description 8
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 7
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 7
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 7
- 206010047249 Venous thrombosis Diseases 0.000 claims description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
- 229960002390 flurbiprofen Drugs 0.000 claims description 7
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000905 indomethacin Drugs 0.000 claims description 7
- 229960004752 ketorolac Drugs 0.000 claims description 7
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 7
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 7
- 229960003464 mefenamic acid Drugs 0.000 claims description 7
- 229960004270 nabumetone Drugs 0.000 claims description 7
- 229960002009 naproxen Drugs 0.000 claims description 7
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 7
- 229960002739 oxaprozin Drugs 0.000 claims description 7
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 description 33
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229960005293 etodolac Drugs 0.000 description 5
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 5
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical group C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000003259 prostaglandin group Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49297503P | 2003-08-07 | 2003-08-07 | |
| PCT/IB2004/002523 WO2005016334A1 (en) | 2003-08-07 | 2004-08-05 | Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508242A JP2007508242A (ja) | 2007-04-05 |
| JP2007508242A5 true JP2007508242A5 (enExample) | 2007-09-20 |
Family
ID=34193159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522433A Withdrawn JP2007508242A (ja) | 2003-08-07 | 2004-08-05 | トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050059741A1 (enExample) |
| EP (1) | EP1660076A1 (enExample) |
| JP (1) | JP2007508242A (enExample) |
| AU (1) | AU2004264722A1 (enExample) |
| CA (1) | CA2534316A1 (enExample) |
| WO (1) | WO2005016334A1 (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK471479A (da) * | 1978-12-13 | 1980-06-14 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
| US5100889A (en) * | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| ZA911453B (en) * | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
| GB9220137D0 (en) * | 1992-09-23 | 1992-11-04 | Pfizer Ltd | Therapeutic agents |
| JPH0753505A (ja) * | 1992-10-01 | 1995-02-28 | Hokuriku Seiyaku Co Ltd | ベンゼンスルホンアミド誘導体及びその用途 |
| US5605917A (en) * | 1994-12-22 | 1997-02-25 | Bristol-Myers Squibb Company | Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog |
| US6586458B1 (en) * | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| WO1999045905A2 (en) * | 1998-03-13 | 1999-09-16 | Pozen Inc. | Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists |
| AU2001264729A1 (en) * | 2000-05-22 | 2001-12-03 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
| ES2282469T3 (es) * | 2001-09-19 | 2007-10-16 | Nycomed Gmbh | Combinacion de un nsaid y un inhibidor de pde-4. |
| JP2005533830A (ja) * | 2002-07-09 | 2005-11-10 | ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ | トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ |
-
2004
- 2004-08-05 CA CA002534316A patent/CA2534316A1/en not_active Abandoned
- 2004-08-05 JP JP2006522433A patent/JP2007508242A/ja not_active Withdrawn
- 2004-08-05 WO PCT/IB2004/002523 patent/WO2005016334A1/en not_active Ceased
- 2004-08-05 AU AU2004264722A patent/AU2004264722A1/en not_active Abandoned
- 2004-08-05 US US10/911,644 patent/US20050059741A1/en not_active Abandoned
- 2004-08-05 EP EP04744172A patent/EP1660076A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080113973A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
| JP2007510736A5 (enExample) | ||
| JP2005533830A5 (enExample) | ||
| Krasniqi et al. | Analgesics use in dentistry | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| Seymour | Drug interactions in dentistry | |
| JP2007508242A5 (enExample) | ||
| JP2011514354A5 (enExample) | ||
| TW200401636A (en) | Drug composition for blood sugar control | |
| AU2015274895A1 (en) | Fixed dose combination for pain relief without edema | |
| ES2398960T3 (es) | Composición farmacéutica novedosa y su uso en un método para el tratamiento de pacientes con cangestión mucosa de las vías respiratorias altas | |
| US20210283096A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| ES2811904T3 (es) | Composición farmacéutica que comprende bisoprolol y perindopril | |
| JP2007513095A5 (enExample) | ||
| JP2007508242A (ja) | トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法 | |
| RU2530628C1 (ru) | Фармацевтическая композиция и набор для лечения и/или предупреждения нарушений, связанных с ожирением, и способ лечения и/или предупреждения нарушений, связанных с ожирением | |
| RU2423979C2 (ru) | Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей | |
| BRMU8603054U2 (pt) | embalagem ou kit de medicamentos ou apresentaÇço para a administraÇço harmoniosa de medicamentos no tratamento da hipertensço, da angina e de outros tipos de doenÇas cardiovasculares | |
| Schmidt | Focus on K-Fenak Anti-Inflammatory® tablets | |
| WO2024221023A1 (en) | Anti-inflammatory, analgesic and antipyretic suppository | |
| WO2007093020A1 (en) | Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. | |
| Agent | Pr NITROLINGUAL® PUMPSPRAY | |
| WO2012011118A2 (en) | Development of a fixed dose combination dosage form containing ramipril and carvedilol | |
| Standard et al. | NITROLINGUAL® PUMPSPRAY | |
| Goodchild | Appropriate analgesic prescribing for the general dentist |